A5039077873- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Breast Implant and Reconstruction
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Gene expression and cancer classification
- Immune cells in cancer
- Drug Transport and Resistance Mechanisms
- AI in cancer detection
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- Head and Neck Cancer Studies
- Health Systems, Economic Evaluations, Quality of Life
- Single-cell and spatial transcriptomics
- Economic and Financial Impacts of Cancer
- Lymphatic System and Diseases
Fujian Medical University
2020-2024
Union Hospital
2020-2024
Fujian Provincial Cancer Hospital
2023-2024
Qingdao University
2020
Affiliated Hospital of Qingdao University
2020
Sun Yat-sen Memorial Hospital
2020
Sun Yat-sen University
2020
We aimed to analysis the impact of chemotherapy and establish prediction models prognosis in early elderly triple negative breast cancer (eTNBC) by using machine learning. enrolled 4,696 patients SEER Database who were 70 years or older, diagnosed with primary TNBC(larger than 5 mm), from 2010 2016. The propensity-score matched method was utilized reduce covariable imbalance. Univariable multivariable analyses used compare cancer-specific survival(BCSS) overall survival(OS). Nine developed...
can be considered during the neoadjuvant treatment in all patients who qualify for single-targeted therapy. 2 The KRISTINE study (1) confirmed effectiveness and safety of TCbHP regimen treatment, Therefore, is preferred preoperative treatment. 3The NeoSphere (2) that adding pertuzumab to TH could further increase pCR rate HER-2-positive patients.However, above study, surgery was performed after 4 cycles with THP, dualtargeted therapy suspended then continued 3 FEC therapy.The clinical...
Purpose: The aim of our study was to evaluate the different clinicopathological characteristics and prognostic factors for occult non-occult breast cancer. Methods: 572 OBC cases 117,217 non-OBC patients between 2004 2015 selected from Surveillance, Epidemiology, End Results (SEER) database. We analyzed survival outcomes patients. Furthermore, propensity score matching method utilized reduce influences baseline differences in demographic clinical on outcome differences. Univariable...
Aims: Currently, there are many approaches available for neoadjuvant therapy human epidermal growth factor receptor 2 (HER2)-positive breast cancer that improve therapeutic efficacy but also controversial. We conducted a two-step Bayesian network meta-analysis (NMA) to compare odds ratios (ORs) pathologic complete response (PCR) and safety endpoints. Methods: The Cochrane Central Register of Controlled Trials, PubMed, Embase, online abstracts from the American Society Clinical Oncology San...
Abstract Background monarchE, a phase 3, open-label, randomized study evaluating endocrine therapy with or without abemaciclib in patients node positive, HR+, HER2-, high risk early breast cancer, resulted statistically significant improvement invasive disease-free survival (IDFS) at pre-planned interim analysis. Ki-67, marker of cellular proliferation was used addition to other clinical and/or pathological features identify whose cancer may be higher recurrence. A key secondary endpoint...
Abemaciclib was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved globally in adjuvant setting for high-risk hormone-receptor positive (HR+)/human epidermal growth factor 2 negative (HER2-) early breast cancer (EBC), based on phase III monarchE trial.
An imbalance of intracellular iron metabolism can lead to the occurrence ferroptosis. Ferroptosis be a factor in remodeling immune microenvironment and affect efficacy cancer immunotherapy. How combine ferroptosis-promoting modalities with immunotherapy suppress triple-negative breast (TNBC) has become an issue great interest therapy. However, potential biomarkers related regulation TNBC remain poorly understand.We constructed optimal prognostic TNBC-IMRGs (iron immune-related genes)...
Abstract Background This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in female aged 70 years or older diagnosed with breast cancer, which is still controversial. Methods retrospective enrolled cancer women + following mastectomy from Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was performed reduce covariable imbalance. A nomogram created predict 1,3,5-years overall survival (OS) divide patients into three risk...
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive disease. Developing new candidate biomarkers for chemotherapy response possible therapeutic targets has become an urgent clinical need. Small ubiquitin-like modifiers (SUMOs) mediate post-translational modifications (SUMOylation) been shown to be involved in numerous biological processes. However, the role of SUMOylation TNBC yet elucidated.Method: The mRNA expression SUMO1/2/3 was analyzed by Cancer...
The stem characteristics of tumor cells have been proposed in theory very early, and we can use the signature gene expression to speculate stemness cells. However, systematic studies on breast cancer as well subtypes, relationship between metastasis prognosis, are still lacking. In present research, using transcriptome data patients with TCGA database, a prediction model was utilized derive patients' tumors. We compared values among different subtypes differences metastasis. COX regression...
The discovery of noncoding RNAs (ncRNAs) offers new options for cancer-targeted therapy. This study is aimed at exploring the regulatory function LINC00092 on breast cancer (BC) oxidative stress and glycolysis, along with internal mechanism concerning pyruvate carboxylase (PC). Bioinformatics analysis was used to explore (or friend leukemia virus integration 1 (FLI1)) expression BC progression, as well glycolysis in BC. After overexpression or silence, cell viability, proliferation,...
Abstract Background: The primary results from the OlympiA trial were recently reported (NEJM, 2021) after an interim analysis demonstrated statistically significant invasive disease-free survival (DFS) benefit 1 year of olaparib (OL) vs. placebo (PL) 2.5 yrs median follow-up. Although there fewer deaths with OL than PL, overall (OS) did not reach statistical significance threshold prespecified for analysis. initial publication also on adverse event profile, which was similar to that...
Abstract Background: HER2-targeted therapies combined with chemotherapy have improved survival outcomes for patients metastatic HER2-positive breast cancer. However, progressed after several lines of anti-HER2 combinational therapies, the overall (OS) remained unfavorable. Prior studies showed that immunotherapy in combination or targeted therapy could significantly prolong OS cancer patients, especially triple-negative Reports are still limited. Here we reported preliminary results from an...
Abstract Objective: Although neoadjuvant chemotherapy (NCT) is a standard approach for operable triple negative breast cancer (TNBC), the potential risks brought by it should also be noticed. Is expanding indication of NCT to T1cN0M0 population appropriate? We conducted an investigation compare long-term survival small tumor TNBC between and adjuvant (ACT). Methods: For this propensity-matched analysis, we used data from SEER database. enrolled 1183 cases with 2550 ACT who are AJCC clinical...
Abstract Background: The numerous but conflicting first-line treatment regimens for Her-2 positive advanced breast cancer necessitate a comprehensive evaluation to inform clinical decision-making. In this study, we conducted Bayesian network meta-analysis (NMA) compare the efficacy and safety of different interventions. Methods: We systematically searched relevant randomized controlled trials (RCTs) in Pubmed, Embase, Cochrane Library online abstracts published by ASCO, SABCS. NMA was...
Abstract Background: Based on the expression of estrogen receptor (ER), progesterone (PR) and human epidermal growth factor 2 (HER2), a special subtype breast cancer which expresses all three receptors can be distinguished, namely triple-positive (TPBC). TPBC patients has higher risk recurrence lower survival rate compared to other luminal cancers. However, there are few studies predicting molecules prognosis treatment response for TPBC. Methods: Proliferation essential genes (PEGs) were...
Abstract Purpose Breast cancer is the most common in women. The aim of this study was to build a prognostic signatures model based on immune score ESTIMATE algorithm predict survival breast patients. Methods RNA‐seq expression data and clinical characteristics patients were derived from TCGA GSE88770 GEO. used calculate patients' scores obtain DEGs. LASSO Cox regression applied select genes. Survival analysis ROC curve evaluate predictive efficacy model. Independent factors assessed using...
Primary breast lymphoma (PBL) is a rare disease whose epidemiological features, treatment principles, and factors used for the patients' prognosis remain controversial.
Abstract Background: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes (two different shared by trastuzumab and pertuzumab). KN046 blocks both PD-L1 interaction with PD-1/CD80 CTLA-4 CD80/CD86. Our on-going multi-centered phase II trial (NCT04521179) demonstrated in advanced HER2-positive breast cancer (HER2+ BC) patients, who have progressed after prior anti-HER2 combinational therapies, the objective response rate (ORR) of this chemo-free therapy...
522 Background: In monarchE, abemaciclib (oral CDK4&6 inhibitor) plus endocrine therapy (ET) as adjuvant treatment for HR+, HER2- high risk early breast cancer (EBC), demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) compared to ET alone. Here we present the efficacy and safety analysis of Chinese patients from monarchE. Methods: The overall study design was reported previously. Eligible were randomized receive (150 mg BID 2 years) combined...
Abstract Purpose Breast cancer-related lymphedema (BCRL) is a common complication in breast cancer survivors. Most BCRL studies have focused on patients receiving adjuvant chemotherapy, and relatively little attention has been paid to with neoadjuvant chemotherapy (NAC). This study aimed investigate the risk factors associated Chinese women undergoing NAC axillary lymph node dissection (ALND). Methods In our institution, this cohort collected data from 336 clinically node-positive who...